Davita Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Davita Inc trades at $179.07 (market cap $11.29B), while State Street Technology Select Sector SPDR ETF trades at $198.68 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 11.7× Davita Inc's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| DVA | XLK | |
|---|---|---|
Market Cap | $11.29B | $132.55B |
Volume | 582,204 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $202.00 |
52-Week Low | $103.87 | $127.49 |
Typical Hold Time | 113 Days | 50 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
XLK, the Technology Select Sector SPDR ETF, trades at $197.73, down 1.82% amid broader tech pressure. The technical outlook is bullish based on moving averages, with support at $196 and resistance at $201. Recent news highlights concentration risks in semiconductor holdings and competition from thematic AI ETFs.
The ETF faces headwinds from potential Fed rate hikes and sector rotation but benefits from strong AI investment themes. Risks include overconcentration in mega-cap tech and interest rate sensitivity, while its low expense ratio and diversified tech exposure offer a defensive growth play.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →